XM does not provide services to residents of the United States of America.
S
S

Sobi

News

Danske Bank, Lotus Bakeries NV, Vesuvius

EUROPE RESEARCH ROUNDUP-Danske Bank, Lotus Bakeries NV, Vesuvius Aug 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Lotus Bakeries NV and Vesuvius, on Tuesday. HIGHLIGHTS * Abrdn Plc ABDN.L : Morgan Stanley raises target price to 160p from 149p * Danske Bank DANSKE.CO : Morgan Stanley initiates coverage with overweight rating * Lotus Bakeries NV LOTB.BR : Berenberg raises target price to EUR 10,300 from EUR 9,000 *
A
A
A
B
C
D
E
F
H
H
K
L
M
M
N
O
S
S
S
S
S
H
A
S
U

SOBI, Apellis Announce Positive Topline Results From VALIANT Study

BRIEF-SOBI, Apellis Announce Positive Topline Results From VALIANT Study Aug 8 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI AND APELLIS ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VALIANT STUDY OF PEGCETACOPLAN IN C3G AND PRIMARY IC-MPGN MET PRIMARY ENDPOINT, ACHIEVING STATISTICALLY SIGNIFICANT 68% (P PLANS TO SUBMIT A MARKETING APPLICATION WITH EUROPEAN MEDICINES AGENCY (EMA) IN 2025 APELLIS ALSO PLANS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION TO U.S.
S

Top of the Street: Sika, Haleon, Anglo American, VAT Group

BUZZ-Top of the Street: Sika, Haleon, Anglo American, VAT Group A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Stifel raises Swiss chemicals maker Sika SIKA.S to "buy" from "hold" after it increased its PT to CHF 270, which implies an upside of 11%, following the recent share price drop ** Goldman Sachs cuts consumer healthcare company Haleon HLN.L to "neutral" from "buy", as it sees limited catalysts to drive near term price performance, with Pfizer's
D
N
P
S
S
A

Jefferies cuts SOBI to 'hold' as competition weighs

BUZZ-Jefferies cuts SOBI to 'hold' as competition weighs ** Jefferies cuts Swedish Orphan Biovitrum SOBIV.ST to "hold" from "buy", citing increasing competition pressure for the Swedish drug maker ** Brokerage sees Merck's MRK.N positive data for antibody against lung infections caused by respiratory syncytial virus (RSV), clesrovimab, as a downsid
G
S

Sobi Raises 2024 Revenue Growth Outlook

BRIEF-Sobi Raises 2024 Revenue Growth Outlook July 16 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : OUTLOOK 2024: REVENUE IS ANTICIPATED TO GROW BY LOW DOUBLE-DIGIT PERCENTAGE AT CER (PREVIOUSLY HIGH SINGLE-DIGIT) OUTLOOK 2024: ADJUSTED EBITA MARGIN IS ANTICIPATED TO BE IN MID-30S PERCENTAGE OF REVENUE (UNCHANGED) Q2 EBITA WAS SEK 1,486
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.